Alaunos Therapeutics (NASDAQ:TCRT)
Alaunos Therapeutics (NASDAQ:TCRT), a cell therapy firm with a focus on cancer, increased by more than 15% intraday to hit its highest level since August 2021. TCRT shares have been traded more than 3.0 million times as compared to the 65-day average of 2.9 million.
The rally takes place as talk of the company’s presentation at the Sixth International Cancer Immunotherapy Conference circulates on social media.
The Cancer Research Institute (CRI), the European Network for Cancer Immunology (ENCI), and the American Association for Cancer Research will jointly host the event from September 28 to October 1, 2022. (AACR).
Nate Demars, Senior Director of Clinical Operations at TCRT, is scheduled to give a presentation on September 30 during the New York conference in a session devoted to cellular therapy.
“Objective clinical response by KRAS mutation-specific TCR-T cell treatment in previously treated advanced Non-small cell lung cancer” is the title of the presentation.
During the earnings call, Chief Executive of TCRT Kevin Boyle discussed a current Phase 1/2 Trial for its TCR-tailored T-cell therapy and mentioned that preliminary results are anticipated at a scientific conference during Q3.
Tuesday’s opening price for NASDAQ:TCRT shares was $1.63. $1.33 is the 50-day simple moving average for the company. The company’s debt-to-equity ratio is 0.11, its quick ratio is 2.29, and its current ratio is 2.29. Alaunos Therapeutics’s price ranges from $0.41 to $2.43 over a year. $352.37 million is the market cap of the business, and its beta is 0.51, and PE ratio is -6.27.
Therapeutics Alaunos
Adoptive TCR engineered T-cell therapies are created by Alaunos Therapeutics, Inc., a cell therapy business with a focus on oncology that is in the clinical stages. The company is fixated on the treatment of endometrial, colorectal, non-small cell lung, ovarian, pancreatic, and bile duct cancers it develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat the solid tumor.
Featured Image: Megapixl @Dimmid
Author Jowi Kwasu 
